PDX INSIGHTS
PIONEERING CANCER RESEARCH
Home
Collections
Bladder
Breast
Leukemia
Liver
Pancreas
Sarcoma
Omics Tools
Management
Data Management
File Management
Publications
Contact Us
Log In
You need to enable JavaScript to run this app page.
Sarcoma
TCCC-OS51
Model Details
Patient
PDX Model
Histology
Metastasis
Patient Treatment
Patient Information for Model: TCCC-OS51
Contact Model Developer
Model Contact
Model: TCCC-OS51
Model Contact: Nino Rainusso
Institution: TCH Sarcoma PDX Program
Email:
ncrainuss@texaschildrens.org
Patient Information
Model
: TCCC-OS51
Gender
: Female
Race/Ethnicity
: White
Vital Status
: Deceased
Initial Diagnosis
: Osteosarcoma|Osteoblastic
Age at Diagnosis
: 8
Bone Sarcoma Stage
: Metastatic
Primary Site
: Right tibia
Metastasis Sites
: Bone
Clinical Timeline
Clinical Information at Collection
Collection Age
: 8.00
Collection Procedure
: Biopsy
Survival in months
: 22
Time of Specimen Collection
: Diagnosis
Clinical Biomarkers/Mutations
Germline TP53
: Not Performed
Rhabdo Clinical Group
: Not Reported
Cytogenetics
: 46,XX,t(2;7)(q37;q31)[3]/46,XX[17]
Clinical Mutation Panel
: Not Reported
Pathology Information at Collection
Histologic Response
: Not Reported
Treatment Naive
: Yes
Histology Subtypes
: Osteoblastic
Model Information for Model: TCCC-OS51
Model Details - Initial Implantation of Patient Tissue
Host Strain
: NSG
Transplant Specimen Condition
:
Transplant Material
: Tissue Fragment
Transplant Supplements
: None
Transplant Site
: Subcutaneous, flank tumor implantation
Humanization
: None
RECOL4
: Not Reported
Specimen Site
: Right tibia
Mutations (Cancer Gene Census List)
Mutation data is currently not available.
CNV
There are no omics data for this model.
Histology Information for Model: TCCC-OS51
There are no histology images for this model.
Metastasis Information for Model: TCCC-OS51
Patient
PDX
Bone
Lung
Patient Treatment Information for Model: TCCC-OS51
Event Id
Treatment
Treatment Setting
Age at Start
Age at End
Duration
Clinical Response
Pathologic Response
Reason Stopped
10
Methotrexate, Doxorubicin, Cisplatin
Neoadjuvant
8.0
8.25
91 days
Partial Response
Poor response (75% tumor necrosis, tibia; 20% tumor necrosis L3)
Surgical resection (local control & metastectomy)
20
Methotrexate, Doxorubicin, Cisplatin
Adjuvant
8.25
8.66
150 days
No evidence of disease
End of therapy
35
Ifosfamide /Etoposide
Adjuvant
9.08
9.25
62 days
No evidence of disease
End of therapy
Please wait...